A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

• Status: Recruiting
• Trial end date: 2023-12-10
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, prospective, single-arm study to assess safety and efficacy of Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qilu Hospital of Shandong University

Criteria

Inclusion Criteria:

1. Male or female patients aged ≥18 years with a diagnosis of primary or secondary MF by World Health Organization and International Working Group for Myeloproliferative Neoplasms Research and Treat- ment (IWG-MRT) criteria;

2. Received ruxolitinib treatment for ≥3 months.

Exclusion Criteria:

1. Malignant tumors with other progression or myelofibrosis secondary to other diseases;

2. Exclude myelofibrosis patients after splenectomy;

3. Patients with poor compliance with case follow-up or lost to follow-up.